Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Assets: 2016-2025

Historic Assets for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $364.2 million.

  • Akebia Therapeutics' Assets rose 75.80% to $364.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $364.2 million, marking a year-over-year increase of 75.80%. This contributed to the annual value of $220.7 million for FY2024, which is 8.70% down from last year.
  • As of Q3 2025, Akebia Therapeutics' Assets stood at $364.2 million, which was up 5.37% from $345.6 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Assets registered a high of $628.7 million during Q1 2021, and its lowest value of $207.1 million during Q3 2024.
  • Its 3-year average for Assets is $264.1 million, with a median of $241.7 million in 2023.
  • In the last 5 years, Akebia Therapeutics' Assets crashed by 52.12% in 2023 and then skyrocketed by 75.80% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Assets (Quarterly) stood at $529.3 million in 2021, then plummeted by 32.74% to $356.1 million in 2022, then tumbled by 32.12% to $241.7 million in 2023, then declined by 8.70% to $220.7 million in 2024, then spiked by 75.80% to $364.2 million in 2025.
  • Its Assets stands at $364.2 million for Q3 2025, versus $345.6 million for Q2 2025 and $310.2 million for Q1 2025.